Kodiak Sciences Inc. (BMV:KOD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 40.54B +915.2% |
| Revenue (ttm) | n/a |
| Net Income | -4.16B |
| EPS | -74.94 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Average Volume | 487 |
| Open | 749.00 |
| Previous Close | 428.00 |
| Day's Range | 749.00 - 749.00 |
| 52-Week Range | 400.00 - 749.00 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | Aug 7, 2026 |
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac... [Read more]
News
Kodiak Sciences upgraded to Buy from Neutral at Chardan
Chardan upgraded Kodiak Sciences (KOD) to Buy from Neutral with a $61 price target “Stellar results” from GLOW2, supported by enthusiasm among key opinion leaders with whom the firm spoke…
Kodiak Sciences reports Q1 EPS (94c), consensus ($1.01)
Kodiak ended Q1 with $169.5M cash and cash equivalents and believes that current cash and cash equivalents will support operations into 2027. “Kodiak has entered 2026 with continued momentum and…
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
Kodiak Sciences Earnings release: Q1 2026
Kodiak Sciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Kodiak Sciences Quarterly report: Q1 2026
Kodiak Sciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supp...
Kodiak Sciences Proxy statement: Proxy filing
Kodiak Sciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Kodiak Sciences Proxy statement: Proxy filing
Kodiak Sciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Kodiak Sciences falls -8.7%
Kodiak Sciences (KOD) is down -8.7%, or -$3.72 to $39.09.
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings
Kodiak Sciences stock climbed on Wednesday alongside analyst updates after the company’s most recent earnings report.
Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year
Kodiak reported Q4 results yesterday”Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline progr...
Kodiak Sciences rises 10.7%
Kodiak Sciences (KOD) is up 10.7%, or $4.07 to $42.19.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended Decembe...
Kodiak Sciences Annual report: Q4 2025
Kodiak Sciences has published its Q4 2025 annual report on March 31, 2026.
Kodiak Sciences Earnings release: Q4 2025
Kodiak Sciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Kodiak Sciences options imply 7.3% move in share price post-earnings
Pre-earnings options volume in Kodiak Sciences (KOD) is 2.1x normal with puts leading calls 9:2. Implied volatility suggests the market is anticipating a move near 7.3%, or $2.49, after results…
Kodiak Sciences: Road To $120
Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fu...
Kodiak Sciences price target raised to $80 from $50 at UBS
UBS raised the firm’s price target on Kodiak Sciences (KOD) to $80 from $50 and keeps a Buy rating on the shares. UBS is bullish on both Tarcocimab VEGF and…
Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $58 from $38 and keeps a Buy rating on the shares. The firm cites the…
Kodiak Sciences price target raised to $56 from $39 at Jefferies
Jefferies raised the firm’s price target on Kodiak Sciences (KOD) to $56 from $39 and keeps a Buy rating on the shares. Following strong GLOW2 results showing improved safety/efficacy vs…
Kodiak Sciences stock soars over 60%: what's behind the sharp rally
Shares of Kodiak Sciences surged sharply on Thursday after the biotechnology company reported positive results from a late-stage study of its experimental drug for diabetic retinopathy, a diabetes-rel...
Kodiak Sciences shares surge after eye drug succeeds in late-stage study
Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental drug met the main goal in a late-stage study in patients with diabetes-related eye damage.
Kodiak Sciences reports GLOW2 study of Zenkuda met primary endpoint
Kodiak announced topline results in the GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy. In GLOW2, patients were randomized to receive either sham…
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥...